ApprovalTrail

Approval · Notice of Compliance 4630 · 1996

ZANTAC: Notice of Compliance 4630

Issued March 7, 1996

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
4630
Date
March 7, 1996
Company
Glaxo Wellcome Inc.Mississauga, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
New Drug Submission (NDS)
Submission class
Admin
Therapeutic class
Histamine H2-receptor antagonist

Products in this notice

BrandDINStatus today
ZANTAC02212331Cancelled Post Market
ZANTAC02212358Cancelled Post Market
ZANTAC02212382—
ZANTAC02213397—
ZANTAC02212374Cancelled Post Market
ZANTAC02212366Cancelled Post Market

Medicinal ingredients